- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07620587
The Role of Estradiol and Progesterone on Appetite Regulation and Energy Balance (E2 & P4 in EB)
Aperçu de l'étude
Statut
Description détaillée
The purpose of this study is to further elucidate the individual and combined effects of estradiol and progesterone on appetite-regulating hormones, perceptions of appetite, energy intake, and energy expenditure over a 13 day supplementation period using a randomized controlled trial (RCT) model in males who will be supplemented with each hormone. Sixty healthy, recreationally active male participants will be randomized into one of four possible groups: placebo (PLA; 400 milligrams (mg) per day glucose polymer), estradiol only (E; 1 mg per day for 2 days & 2 mg per day of estradiol for 11 days + 300 mg Polycose), progesterone only (P; Prometrium, 100 mg per day), or combined estradiol and progesterone (E+P; 1 mg per day for 2 days & 2 mg per day of estradiol for 11 days + 300 mg Polycose for estradiol and 100 mg per day of Prometrium) for a total of ~15 per group. Participants will be provided enough daily dose of each treatment dependent on randomization for a total of 13 days and will be instructed to take each supplement orally at the same time each day for the entirety of the intervention. Participants will report to the lab on the 7th day, where they will be fed a standardized meal and then complete either an acute bout of high-intensity interval training (HIIT; 1 minute on, 1 minute off at 90% HRmax) or a period of seated rest (CTRL). Participants will return on day 12 to complete either the HIIT or CTRL session in an identical manner (whichever was not completed on day 7). Blood samples to measure appetite-regulating hormones and perceptions of appetite will be completed pre-exercise, 0-, 30-, 60-, and 120-minutes post-HIIT and CTRL. While participants are receiving the 13 day treatment, free-living energy intake will be assessed for a 3 day period (day before, day of and day after both in lab visits (HIIT/CTRL; days 6-8 and days 11-13) using the Keenoa® mobile application, and energy expenditure will be measured via thigh-worn accelerometers for the same 3 day periods. An ad libitum meal will also be provided following the HIIT and CTRL sessions.
We anticipate publishing this RCT in two separate manuscripts. Manuscript #1 will focus on the potential effects on the appetite-regulating hormones (acylated ghrelin, GLP-1, CCK) and perceptions of appetite. Manuscript #2 will focus on potential effects on energy balance from the measures of energy intake (including free-living and ad-libitum meal intake) and energy expenditure.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Jessica Tucker, MKin, PhD Candidate
- Numéro de téléphone: 4919 519-884-1970
- E-mail: tuck5010@mylaurier.ca
Lieux d'étude
-
-
Ontario
-
Waterloo, Ontario, Canada, N2L 3C5
- Recrutement
- Energy Metabolism Research Laboratory
-
Contact:
- Jessica Tucker, MKin, PhD Candidate
- Numéro de téléphone: 4919 519-884-1970
- E-mail: tuck5010@mylaurier.ca
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
La description
Inclusion Criteria:
- ages 18-30 years
- deemed healthy using Canadian Society for Exercise Physiology Get Active Questionnaire (CSEP-GAQ)
- non-smoking
Exclusion Criteria:
- failure to meet inclusion criteria
contraindications to exercise as indicated by the (CSEP-GAQ)
- hypersensitivity or allergy to estradiol, progesterone, cellulose, or capsule components
- having been diagnosed with any metabolic disease (ie. diabetes, metabolic syndrome) or current diagnosis of overweight/obesity (BMI > 30.0)
- personal of family history of stroke or thrombotic (blood clot) disease, blood clot disorder, venous or arterial thromboembolic disease, or any possible blood clotting disease
- currently taking anticoagulants, antidiabetic medications, cyclosporine, antihypertensives, and CYP3A4 inducers or inhibitors (e.g., rifampin, ketoconazole, St. John's Wort)
- known liver dysfunction or liver disease
- history of ophthalmic vascular disease
- hormone-dependent malignancies or previous diagnosis of cancer
- recent major surgery (within ~6 months)
- prolonged use of a cast or presence of immobility deeming inability to exercise, diagnosis of inflammatory disorders (ie. rheumatoid arthritis, celiac disease, inflammatory bowel disease)
- history of sensitivity to or extreme nausea/vomiting or any gastrointestinal disorder
- diagnosis of mental health or mood disorder
- presence of abnormal eating behaviours as assessed by the Food Cravings State Questionnaire and the Three Factor Eating Questionnaire
- diagnosed or presence of porphyria or classical migraines
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Placebo Comparator
Participants will be randomized and placed into one of four groups.
The placebo group will receive 400 milligrams (mg) per day of glucose polymer for 13 days total.
The supplementation will be consumed orally at the same time every day for 13 days total.
Participants will not complete more than one arm of the study.
|
See description of intervention arm.
|
|
Expérimental: Estradiol Only
Participants will receive 1 mg per day for 2 days and 2 mg per day of estradiol for 11 days + 300 mg polycose.
The supplementation will be consumed orally at the same time every day for 13 days total.
Participants will not complete more than one arm of the study.
|
See description of intervention arm.
|
|
Expérimental: Progesterone Only
Participants will receive 100 mg per day of Prometrium (oral progesterone) for 13 days.
The supplementation will be consumed orally at the same time every day for 13 days total.
Participants will not complete more than one arm of the study.
|
See description of intervention arm.
|
|
Expérimental: Estradiol and Progesterone Combo
Participants will receive 1 mg per day for 2 days and 2 mg per day estradiolfor 11 days + 300 mg polycose as well as 100 mg per day of Prometrium (oral progesterone).
The supplementation will be consumed orally at the same time every day for 13 days total.
Participants will not complete more than one arm of the study.
|
See description of intervention arm.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Energy balance
Délai: Energy balance will be measured using the data collected surrounding the exercise and no-exercise sessions (6 days total).
|
Energy balance will be calculated as the difference between energy intake and energy expenditure (see below for description of energy intake and energy expenditure).
|
Energy balance will be measured using the data collected surrounding the exercise and no-exercise sessions (6 days total).
|
|
Acylated Ghrelin
Délai: To be measured pre-exercise, 0 minutes post-exercise, 30 minutes post-exercise, 60 minutes post-exercise, and 120 minutes post-exercise.
|
Appetite-stimulating hormone acylated ghrelin to be measured via commercially available ELISA kits (pg/mL).
|
To be measured pre-exercise, 0 minutes post-exercise, 30 minutes post-exercise, 60 minutes post-exercise, and 120 minutes post-exercise.
|
|
Glucagon-like Peptide 1 (GLP-1)
Délai: To be measured pre-exercise, 0 minutes post-exercise, 30 minutes post-exercise, 60 minutes post-exercise, and 120 minutes post-exercise.
|
Appetite-inhibiting hormone GLP-1 to be measured via commercially available ELISA kits (pmol/L).
|
To be measured pre-exercise, 0 minutes post-exercise, 30 minutes post-exercise, 60 minutes post-exercise, and 120 minutes post-exercise.
|
|
Cholecystokinin (CCK)
Délai: To be measured pre-exercise, 0 minutes post-exercise, 30 minutes post-exercise, 60 minutes post-exercise, and 120 minutes post-exercise.
|
Appetite-inhibiting hormone CCK to be measured via commercially available ELISA kits (pg/ml).
|
To be measured pre-exercise, 0 minutes post-exercise, 30 minutes post-exercise, 60 minutes post-exercise, and 120 minutes post-exercise.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Appetite perceptions
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Subjective appetite perceptions will be assessed using visual analogue scales (VAS) validated for four perceptions: hunger (i.e., "How hungry do you feel?"), satisfaction (i.e., "How satisfied do you feel?"), fullness (i.e., "How full do you feel?"), and prospective food consumption (i.e., "How much do you think you can eat?").
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Food Preferences
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
For food preferences, a state food preference questionnaire is a survey or questionnaire used to gather information about individuals' food preferences, and dietary habits.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Ad libitum meal energy intake
Délai: At the end of each in-lab session (exercise and seated rest; 2 meals total).
|
A post in-lab session meal will be provided to all participants to determine their ad libitum energy intake for this meal by measuring the food provided before the meal as well as the amount of food not consumed using an analog scale .
|
At the end of each in-lab session (exercise and seated rest; 2 meals total).
|
|
Free-living energy intake
Délai: Day before, day of, and day after each in-lab session (6 days total).
|
Participants will complete a 3 day food record around each in lab session using a mobile application (Keenoa®) monitored by a registered dietician.
|
Day before, day of, and day after each in-lab session (6 days total).
|
|
Energy expenditure
Délai: Day before, day of, and day after each in-lab session (6 days total).
|
Energy expenditure will be measured for the same 3 days of the food records around both in-lab sessions measured using a thigh-worn accelerometer.
|
Day before, day of, and day after each in-lab session (6 days total).
|
|
Estradiol
Délai: Pre-exercise only.
|
Sex hormone estradiol measured via radioimmunoassay (pg/mL).
|
Pre-exercise only.
|
|
Progesterone
Délai: Pre-exercise only.
|
Sex hormone progesterone measured via radioimmunoassay (ng/mL).
|
Pre-exercise only.
|
|
Testosterone
Délai: Pre-exercise only.
|
Sex hormone testosterone measured via radioimmunoassay.
|
Pre-exercise only.
|
|
Blood glucose
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Will be measured using biochemical assays prior to and following treatment.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Insulin
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Will be measured using biochemical assays prior to and following treatment.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
C-Peptide
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Will be measured using biochemical assays prior to and following treatment.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Peripheral Blood Mononuclear Cells
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured by flow cytometry and biochemical assays/arrays both before and after treatment and before and after an acute bout of exercise.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Inflammatory Cytokines
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured by flow cytometry and biochemical assays/arrays both before and after treatment and before and after an acute bout of exercise.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Brain-derived Neurotrophic Factor (BDNF)
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via ELISA kits.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Cathepsin B
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via ELISA kits.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Irisin
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via ELISA kits.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Klotho
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via ELISA kits.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Adrenocorticotropic Hormone
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Dickkopf-1 (DKK-1)
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Fibroblast Growth Factor 23 (FGF-23)
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Interleukin 1B (IL-1B)
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Interleukin-6 (IL-6)
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Tumor Necrosis Factor (TNF)
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Osteocalcin
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Osteopontin
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Osteoprotegerin (OPG)
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Parathyroid Hormone (PTH)
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Sclerostin
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Leptin
Délai: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Tom J Hazell, PhD, Wilfrid Laurier University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- EMRL-25-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Placebo Comparator
-
SamA Pharmaceutical Co., LtdInconnueBronchite aiguë | Infection aiguë des voies respiratoires supérieuresCorée, République de
-
Heptares Therapeutics LimitedComplétéPharmacocinétique | Des problèmes de sécuritéRoyaume-Uni
-
National Institute on Drug Abuse (NIDA)ComplétéConsommation de cannabisÉtats-Unis
-
AkesoPas encore de recrutementLa dermatite atopiqueChine
-
Chong Kun Dang PharmaceuticalInconnueHypertension | DyslipidémiesCorée, République de
-
CellmedisMedical Network Sp. z o.o.Pas encore de recrutement
-
Texas A&M UniversityNutraboltComplétéRéponse du glucose et de l'insuline
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyComplétéSujets masculins atteints de diabète de type II (T2DM)Allemagne
-
Samjin Pharmaceutical Co., Ltd.ComplétéEn bonne santéCorée, République de